Amersham Biosciences has filed a lawsuit against PerkinElmer
alleging that the latter has infringed on two of Amersham's patents
for a reagent technology used in the development of new drugs.
After Amersham confirmed yesterday that it had received a bid from
an unnamed suitor wishing to buy the entire company, its shares
rose more than 16 per cent; both J&J and Roche are in the
rumour mill.
Amersham Biosciences has added a mouse genome product in its
CodeLink range, used for drug target identification, pathway
characterisation and drug effect predictions.
Amersham Biosciences has added to its range of CyDye mono-reactive
fluor dyes with two products used for labelling proteins or
antibodies in protein array experiments.